CEL-SCI plans U.S. study and Saudi deal for head and neck drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy
June 16, 2026 8:00 AM EDTU.S. Confirmatory Registration Study expected to begin Summer 2026
Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of life
Saudi partnership includes a 50%/50% net revenue share and supports potential patient access in one of the Middle East's largest oncology markets
VIENNA, Va.--(BUSINESS... More
